Sage Therapeutics, INC

Sage Therapeutics, Inc. has successfully completed its acquisition by Supernus Pharmaceuticals, Inc. through a tender offer and subsequent merger, leading to its delisting from The Nasdaq Global Market.

Sage Therapeutics announced robust second quarter 2025 financial results, highlighted by significant ZURZUVAE revenue growth, as it progresses towards its acquisition by Supernus Pharmaceuticals.

Supernus Pharmaceuticals, Inc. has entered into a definitive agreement to acquire Sage Therapeutics, Inc. for an upfront cash payment of $8.50 per share plus a contingent value right of up to $3.50 per share, totaling up to $12.00 per share, aiming to expand its CNS product offerings and achieve significant synergies.

Sage Therapeutics, Inc. announced that its stockholders approved the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as its independent auditor, the non-binding advisory vote on executive compensation, and an amendment to its 2014 Employee Stock Purchase Plan at its Annual Meeting on June 11, 2025.

Sage Therapeutics announces Q1 2025 financial results, highlighting growth in ZURZUVAE revenue and shipments for postpartum depression treatment, while a strategic alternatives review remains ongoing.

Laura Gault, M.D., Ph.D., Chief Medical Officer of Sage Therapeutics, has resigned effective March 21, 2025, to pursue a new opportunity.

Sage Therapeutics announced a significant reduction in net losses and substantial revenue growth for the second quarter and first half of 2025, driven by ZURZUVAE commercialization, while navigating a pending acquisition by Supernus Pharmaceuticals and ongoing legal challenges.

Sage Therapeutics reports a net loss of $62.2 million for Q1 2025, focusing on ZURZUVAE commercialization and pipeline development.

Sage Therapeutics reported its Q3 2024 financial results, highlighting the commercial progress of ZURZUVAE for postpartum depression and a strategic reorganization to prioritize key programs.

Sage Therapeutics' Q2 2024 results highlight ongoing commercialization of ZURZUVAE for postpartum depression and continued pipeline development, particularly for dalzanemdor.

Sage Therapeutics reported its first quarter 2024 results, highlighting the commercial launch of ZURZUVAE for postpartum depression and ongoing clinical trials for other brain health therapies.

Sage Therapeutics reports its full year 2024 results, highlighting commercialization efforts for ZURZUVAE, pipeline prioritization, and the initiation of a strategic review following an unsolicited acquisition proposal from Biogen.

Sage Therapeutics' 10-K filing highlights the commercial launch of ZURZUVAE for postpartum depression, ongoing clinical trials, and strategic collaborations.

Michael C. Quirk, Chief Scientific Officer of Sage Therapeutics, has disposed of all his common stock, restricted stock units, and stock options following the company's merger with Supernus Pharmaceuticals, receiving cash and contingent value rights.

Sage Therapeutics Director Jessica Federer disposed of 21,500 stock options as part of the company's merger with Supernus Pharmaceuticals, receiving cash and contingent value rights.

Sage Therapeutics' Chief Operating Officer, Christopher Benecchi, disposed of all his common stock, restricted stock units, and stock options as a result of the company's merger with Supernus Pharmaceuticals, Inc. becoming effective.

A director of Sage Therapeutics, Michael F. Cola, disposed of stock options as part of the company's merger with Supernus Pharmaceuticals, receiving cash and contingent value rights.

A director of Sage Therapeutics, Inc. disposed of common stock and stock options as part of the company's merger with a Supernus Pharmaceuticals subsidiary, receiving cash and contingent value rights.

A director of Sage Therapeutics, George Golumbeski, has reported the disposition of common stock and stock options as a result of the company's merger with Supernus Pharmaceuticals, Inc., effective July 31, 2025.

Sage Therapeutics will hold its annual stockholder meeting on June 11, 2025, featuring proposals including the election of directors, ratification of the company's accounting firm, executive compensation approval, and an amendment to the Employee Stock Purchase Plan.

Sage Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the appointment of auditors, approve executive compensation, and amend the Employee Stock Purchase Plan.

Sage Therapeutics announces its annual stockholder meeting to be held on June 10, 2024, with key voting items including the election of directors and ratification of the company's accounting firm.

Sage Therapeutics is holding its 2024 Annual Meeting of Stockholders virtually on June 10, 2024, to vote on key proposals, including the election of directors and approval of the 2024 Equity Incentive Plan.

Biogen Inc. and Biogen MA Inc. have fully divested their entire beneficial ownership in Sage Therapeutics, Inc., selling all 6,241,473 shares at $8.53 per share.

Biogen Inc. plans to tender its 10% stake in Sage Therapeutics, Inc. following the rejection of its acquisition proposal and Sage's subsequent merger agreement with Supernus Pharmaceuticals, Inc.

Biogen Inc. and its subsidiary Biogen MA Inc. have submitted a non-binding proposal to acquire all outstanding shares of Sage Therapeutics, Inc. not currently owned by them for $7.22 per share in cash.

A group of investment entities led by Madison Avenue Partners has filed an amended Schedule 13G, reporting zero beneficial ownership in Sage Therapeutics, Inc. common stock.

A group of investment entities led by Madison Avenue Partners LP has disclosed beneficial ownership of 9.7% of Sage Therapeutics, Inc.'s common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting a 5.21% beneficial ownership stake in Sage Therapeutics Inc.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 7.2% passive beneficial ownership stake in Sage Therapeutics Inc. as of March 31, 2025.

A group of investment entities associated with Madison Avenue, including Madison Avenue International LP and Eli Samaha, have disclosed a passive 8% beneficial ownership stake in Sage Therapeutics, Inc.

FMR LLC and Abigail P. Johnson have filed an Amendment No. 16 to their Schedule 13G, disclosing a beneficial ownership of 0.8% of Sage Therapeutics Inc.'s common stock as of February 28, 2025.